KR20210061332A - 뇌전증 치료 방법 - Google Patents

뇌전증 치료 방법 Download PDF

Info

Publication number
KR20210061332A
KR20210061332A KR1020217004603A KR20217004603A KR20210061332A KR 20210061332 A KR20210061332 A KR 20210061332A KR 1020217004603 A KR1020217004603 A KR 1020217004603A KR 20217004603 A KR20217004603 A KR 20217004603A KR 20210061332 A KR20210061332 A KR 20210061332A
Authority
KR
South Korea
Prior art keywords
epilepsy
compound
fenfluramine
pharmaceutically acceptable
norfenfluramine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217004603A
Other languages
English (en)
Korean (ko)
Inventor
제프리 폴 베차드
로빈 폴 쉐링턴
장-자크 알렉산더 카디오
파리사 카리미 타리
Original Assignee
제논 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제논 파마슈티칼스 인크. filed Critical 제논 파마슈티칼스 인크.
Publication of KR20210061332A publication Critical patent/KR20210061332A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217004603A 2018-07-27 2019-07-26 뇌전증 치료 방법 Ceased KR20210061332A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711051P 2018-07-27 2018-07-27
US62/711,051 2018-07-27
PCT/US2019/043765 WO2020023923A1 (en) 2018-07-27 2019-07-26 Method for treating epilepsy

Publications (1)

Publication Number Publication Date
KR20210061332A true KR20210061332A (ko) 2021-05-27

Family

ID=67551433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004603A Ceased KR20210061332A (ko) 2018-07-27 2019-07-26 뇌전증 치료 방법

Country Status (20)

Country Link
US (1) US20200030260A1 (enExample)
EP (1) EP3829558B1 (enExample)
JP (1) JP2021530541A (enExample)
KR (1) KR20210061332A (enExample)
CN (1) CN112930175A (enExample)
AU (1) AU2019310600A1 (enExample)
BR (1) BR112021001135A2 (enExample)
CA (1) CA3106031A1 (enExample)
CL (1) CL2021000196A1 (enExample)
CO (1) CO2021002087A2 (enExample)
CR (1) CR20210095A (enExample)
EA (1) EA202190369A1 (enExample)
ES (1) ES2988130T3 (enExample)
IL (1) IL280128A (enExample)
MA (1) MA53329A (enExample)
MX (1) MX2021000987A (enExample)
PE (1) PE20211065A1 (enExample)
PH (1) PH12021550176A1 (enExample)
SG (1) SG11202100682YA (enExample)
WO (1) WO2020023923A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
WO2020047312A1 (en) * 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
CN114127150A (zh) * 2019-07-18 2022-03-01 巴斯夫欧洲公司 脲基甲酸酯基分散剂
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20230078820A1 (en) * 2021-09-01 2023-03-16 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (enExample) 1960-11-05
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
WO1995033455A1 (en) * 1994-06-03 1995-12-14 Elmaleh David R Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
JP2001524124A (ja) 1997-05-07 2001-11-27 ガレン（ケミカルズ）リミティド テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
US6591909B1 (en) 2001-12-20 2003-07-15 Halliburton Energy Services, Inc. Whey protein retarder
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CA3204599A1 (en) * 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
WO2020023923A1 (en) 2020-01-30
CA3106031A1 (en) 2020-01-30
EA202190369A1 (ru) 2021-06-10
AU2019310600A1 (en) 2021-02-11
EP3829558C0 (en) 2024-07-03
MX2021000987A (es) 2021-06-15
CL2021000196A1 (es) 2021-12-31
CO2021002087A2 (es) 2021-04-30
CR20210095A (es) 2021-06-01
EP3829558B1 (en) 2024-07-03
ES2988130T3 (es) 2024-11-19
SG11202100682YA (en) 2021-02-25
JP2021530541A (ja) 2021-11-11
IL280128A (en) 2021-03-01
MA53329A (fr) 2022-03-02
PE20211065A1 (es) 2021-06-09
EP3829558A1 (en) 2021-06-09
BR112021001135A2 (pt) 2021-04-20
CN112930175A (zh) 2021-06-08
US20200030260A1 (en) 2020-01-30
PH12021550176A1 (en) 2021-10-11

Similar Documents

Publication Publication Date Title
EP3829558B1 (en) Method for treating epilepsy
EP3458449B1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
TWI465452B (zh) 螺－吲哚酮化合物之鏡像異構物及其作為治療劑之用途
US10766858B2 (en) Substituted benzamides and methods of use thereof
EP3551626B1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
CA3225008A1 (en) Safer psychoactive compositions
CN109475514A (zh) 使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法
US11325902B2 (en) Benzenesulfonamide compounds and their use as therapeutic agents
US20200087239A1 (en) Therapeutic compounds and methods of use thereof
JP5947907B2 (ja) Ｋｃｎｑカリウムチャネル作動薬として使用できる新規な化合物、その製造方法および用途
JP6808154B2 (ja) アダマンタン誘導体およびその使用
US20250011279A1 (en) Deuterated organic compounds and uses thereof
HK40045266A (en) Method for treating epilepsy
JPWO2019026994A1 (ja) アダマンチルメチルアミン誘導体およびその医薬としての使用
HK40016430B (en) Benzenesulfonamide compounds and their use as therapeutic agents
HK40016430A (en) Benzenesulfonamide compounds and their use as therapeutic agents
JP2023505054A (ja) 処置方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220725

Comment text: Request for Examination of Application

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241119

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D